Midazolam (Nayzilam) vs Phenobarbital sodium injection (Sezaby)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Epilepsy
Shared mechanism: GABA-A receptor · full Epilepsy pipeline
Midazolam (Nayzilam)
Marketed by UCB
NCT01390220 · Phase 3 · terminated
This was a randomized, triple-blind, placebo-controlled trial in 201 patients, and the primary outcome, control of a seizure cluster with no recurrence, was reached significantly more often with midazolam than with placebo (72 of 134 patients vs 23 of 67, p=0.011).
Reported efficacy
Participants Who Met the Criteria for Treatment Success After Administration of the Double-blind Dose in the Comparative Phase (CP) (6 hours): Participants Who Met the Criteria for Treatment Success After Administration of the Double-blind Dose in the Comparative Phase (CP) (6 hours): USL261 CP 72/134 vs Placebo CP 23/67 (met)
Result source: NCT01390220
Phenobarbital sodium injection (Sezaby)
Marketed by Sun Pharmaceutical Industries
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: March 2028 · NCT07923734 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Epilepsy
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Midazolam (Nayzilam) | Phenobarbital sodium injection (Sezaby) |
|---|---|---|
| Seizure frequency, % change | —Not reported | —Not reported |
| 50% responder rate | —Not reported | —Not reported |
| Seizure freedom | 54.8% vs 38.7%+16.1 vs placeboNCT01999777 | —Not reported |
Seizure frequency, % change
- Midazolam (Nayzilam)
- —Not reported
- Phenobarbital sodium injection (Sezaby)
- —Not reported
50% responder rate
- Midazolam (Nayzilam)
- —Not reported
- Phenobarbital sodium injection (Sezaby)
- —Not reported
Seizure freedom
- Midazolam (Nayzilam)
- 54.8% vs 38.7%+16.1 vs placeboNCT01999777
- Phenobarbital sodium injection (Sezaby)
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Phenobarbital sodium injection (Sezaby): registry results are on file for Epilepsy, but their comparison mappings are not yet available.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Midazolam (Nayzilam): 4 of 4 rows · Phenobarbital sodium injection (Sezaby): 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Midazolam (Nayzilam) |
|---|---|
| Dropout rate | —5 mg + 5 mga NCT01390220 · Phase 3 · Epilepsy · phase 3 show 4 more results—5 mg only NCT01390220 · Phase 3 · Epilepsy · phase 3 —USL261 CP NCT01390220 · Phase 3 · Epilepsy · phase 3 31.2%USL261 TDP NCT01390220 · Phase 3 · Epilepsy · phase 3 0% NCT01999777 · Phase 3 · monotherapy |
| Discontinued due to AEs | —5 mg + 5 mga NCT01390220 · Phase 3 · Epilepsy · phase 3 show 4 more results—5 mg only NCT01390220 · Phase 3 · Epilepsy · phase 3 —USL261 CP NCT01390220 · Phase 3 · Epilepsy · phase 3 5.8%USL261 TDP NCT01390220 · Phase 3 · Epilepsy · phase 3 — NCT01999777 · Phase 3 · monotherapy |
| Serious AEs | 0%5 mg + 5 mga NCT01390220 · Phase 3 · Epilepsy · phase 3 show 4 more results0%5 mg only NCT01390220 · Phase 3 · Epilepsy · phase 3 —USL261 CP NCT01390220 · Phase 3 · Epilepsy · phase 3 0.7%USL261 TDP NCT01390220 · Phase 3 · Epilepsy · phase 3 0% NCT01999777 · Phase 3 · monotherapy |
| Most frequent reported AEs | 5 mg + 5 mga nasal discomfort 16.3% (placebo 7.3%) somnolence 9.3% (placebo 9.8%) throat irritation 7% (placebo 2.4%) NCT01390220 · Phase 3 · Epilepsy · phase 3 show 3 more results5 mg only somnolence 9.9% (placebo 9.8%) headache 6.6% (placebo 0%) nasal discomfort 5.5% (placebo 7.3%) NCT01390220 · Phase 3 · Epilepsy · phase 3 nasal discomfort 16.1% (placebo 7.3%) somnolence 9.6% (placebo 9.8%) lacrimation increased 6.8% (placebo 2.4%) NCT01390220 · Phase 3 · Epilepsy · phase 3 nasal discomfort 16.1% (placebo 16.1%) nausea 9.7% (placebo 3.2%) throat irritation 9.7% (placebo 9.7%) NCT01999777 · Phase 3 · monotherapy |
Notes
- aPopulation comparability has not been reviewed for 1 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Midazolam (Nayzilam)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Midazolam (Nayzilam)'s landscape · Phenobarbital sodium injection (Sezaby)'s landscape